Katherine Davis is a Biotech Deals Reporter at Axios. She specializes in covering topics related to biotech deals, pharmaceuticals, healthcare technology, and artificial intelligence, with a strong focus on the intersection of finance and medicine. Katherine's work has been featured in notable publications including Ad Age, Modern Healthcare, and BioSpace.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Katherine's coverage largely revolves around healthcare, focusing on local developments and corporate news within the industry. For effective outreach, consider providing insights into local healthcare policies or corporate events impacting the Illinois area, particularly Chicago.
Given her emphasis on government announcements and data citations, she may be interested in receiving pitches from authoritative figures such as policymakers or researchers who can provide valuable data-driven insights into local healthcare trends and their impact on the community.
As she focuses extensively on private sector announcements and press releases related to hospitals and clinics within Illinois, engaging with PR representatives of relevant organizations could also be beneficial for pitching newsworthy stories.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Enaz Tewfik, Rosalie Owusu, Lily Perella, Sanjana Gopu, Evan Frilingos, Hosanna Worku, Emily Laycock, Amelia Durden, Gabriel Obleton, Caroline Newbern, Jesse Corso, Jake Westing, Alex Abbate, Aidan Kramer, Julianna Morgan, Delaney Denton, Ansley Kelly, Keith Collier, Lily Kate Akins, Kaleb Tatum, Katherine Davis, Addison Simmons, Ethan Greene, Ashtin Barker, Renee Lipski, Hannarose Schiano, Thaddee Barge
Our favorite photos from the spring 2026 semester.
Strong M&A may boost IPOs and private fundraisings.
A string of biotech acquisitions
Another biotech tests Wall Street appetite for drug developers.
Upsized offerings suggest caution on demand.
The new funding will support commercial expansion beyond imaging.
Investors are watching for a steadier regulator.
The recommendation shows biotech's need for a stable FDA.
Everyone has a goal to travel around the world, and one of the most popular destinations is by far Europe!
Holiday season is fast approaching which means so are sicknesses. Unfortunately, Syracuse University has reached an outbreak of the mumps. Here's everything you need to know about the Syracuse University mumps outbreak.
